Company: CYTK
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001140361-25-013167
Chunk: 100

Company: CYTOKINETICS INC
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 100
---
um had a late Form 4 for his sale transaction dated June 4, 2024 (filed on June 7, 2024), Dr. Malik had a late Form 4 for his sale transaction dated June 13, 2024 (filed June 20, 2024), and Dr. Wierenga had a late Form 4 for his sale transaction dated October 28, 2024 (filed October 31, 2024), in each case due to administrative errors. Other than these late filings, to the Company's knowledge, based solely on our review of the copies of such forms furnished to us and written representations from these officers and directors, all Section 16(a) filing requirements were met during the calendar year ended December 31, 2024. Certain Business Relationships and Related Party Transactions Review, Approval or Ratification of Transactions with Related Parties Our policy is that any transaction with a related party that is required to be reported under applicable SEC rules, other than compensation-related matters and waivers of our Code of Ethics, must be reviewed and approved according to an established procedure. Such a transaction is reviewed and, if appropriate, approved or declined by the Audit Committee as required by the Audit Committee’s charter. We have not adopted specific standards for approval of these transactions, but instead review each such transaction on a case-by-case basis. Our policy is to require that all such compensation-related matters be reviewed by the Compensation Committee and, if approved, submitted to the Board of Directors for review and approval. Any waiver of our Code of Ethics must be reviewed by the Governance Committee and, if approved, must be reported as required under applicable SEC rules. Indemnification of Directors and Officers We provide indemnification for our directors and officers so that they will be free from undue concern about personal liability in connection with their service to us. Under our bylaws, we are required to indemnify our directors and officers to the extent not prohibited under Delaware or other applicable law. We have also entered into indemnification agreements with each of our directors and officers, which require us to indemnify our directors and officers to the fullest extent permitted by Delaware law.

| 70 |     | Cytokinetics, Inc.|2025 Proxy Statement |

TABLE OF CONTENTS Other Matters We know of no other matters to be submitted to the Annual Meeting. If any other matters properly come before the Annual Meeting, it is the intention of the persons named in the Proxy to vote the shares they represent as the Board of Directors may recommend